exercise therapy in neuromuscular disease

64
Exercise Therapy In Neuromuscular Disease 05/10/2013 Maryam Tahmasbi Sohi, MD Fellow in Neuromuscular Medicine Department of Neurology University of Kansas Medical Center

Upload: hadan

Post on 02-Jan-2017

218 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Exercise Therapy in Neuromuscular Disease

Exercise TherapyIn

Neuromuscular Disease

05/10/2013 Maryam Tahmasbi Sohi, MD

Fellow in Neuromuscular Medicine Department of Neurology

University of Kansas Medical Center

Page 2: Exercise Therapy in Neuromuscular Disease

Objectives

• Overview of different types of exercise• Physiologic responses to exercise • Review of available literature for specific

neuromuscular disorders • Recommendations• Will not cover pulmonary rehabilitation

Page 3: Exercise Therapy in Neuromuscular Disease

Different Types of Exercise

Page 4: Exercise Therapy in Neuromuscular Disease

Flexibility Training

• Involves stretching and range of motion • Reduces pain • Reduces spasticity • Increases joint blood flow and lubrication • Prevents contractures

Page 5: Exercise Therapy in Neuromuscular Disease

Aerobic Exercise • Prolonged low-resistance • Dynamic activity • Large muscle groups• Cardiopulmonary effects• American College of Sport Medicine (ACSM)

recommendation:– 30 minutes at 55%-90% of maximum heart rate

or– 40-85% of maximum oxygen uptake (VO2 max) – 4 days a week

Page 6: Exercise Therapy in Neuromuscular Disease

Aerobic Exercise-Benefits• Improves functional exercise capacity • Decreased psychological stress • Improves quality of life • Prevents secondary disease (DM, HTN,

CAD) • Improves sleep • Helps maintain bone density if performed in a

weight bearing manner • Produces greater independence with ADLs in

elderly population

Page 7: Exercise Therapy in Neuromuscular Disease

Maximal Aerobic Capacity (VO2 Max)

• Maximum capacity of an individual's body to transport and use oxygen during incremental exercise

• Reflects the physical fitness of the individual • L/min or mL/kg/min• Graded exercise test while measuring ventilation, O2 and CO2 • O2 consumption remains unchanged despite an increase in workload

Page 8: Exercise Therapy in Neuromuscular Disease
Page 9: Exercise Therapy in Neuromuscular Disease
Page 10: Exercise Therapy in Neuromuscular Disease

Isometric Exercise

• No change in muscle length • No visible joint movement • Primary use is for rehabilitation of joints

with limited ROM due to injury or post op • Only increases strength within a limited range of motion (ROM)

Page 11: Exercise Therapy in Neuromuscular Disease
Page 12: Exercise Therapy in Neuromuscular Disease

Isokinetic Exercise

• Constant speed• Variable resistance

throughout the range of motion

• Lower chance of injury • Athletic training for

strengthening throughout the required ROM

Nautilus- Upright Exercise Bike

Page 13: Exercise Therapy in Neuromuscular Disease
Page 14: Exercise Therapy in Neuromuscular Disease

Concentric Contraction

• Muscle shortens to generate force• Force generated is sufficient to overcome the

resistance

Page 15: Exercise Therapy in Neuromuscular Disease

Eccentric Contraction • Muscle fibers lengthen• Force generated is insufficient to overcome

the external load on the muscle• Mean of decelerating a body part or object,

or lowering a load gently rather than letting it drop

• Negative training

Page 16: Exercise Therapy in Neuromuscular Disease

Sarcomere

Page 17: Exercise Therapy in Neuromuscular Disease

Delayed-Onset Muscle Soreness (DOMS)

• Muscular discomfort and pain • 24±48 h after strenuous exercise• Proximal and distal muscle tendon junctions spreading

throughout the entire muscle• Directly associated with the eccentric exercise (Asmussen

1952, 1956)

• Objective findings:– Strength loss– Reduced range of motion– Elevated serum creatine kinase (CK)

Page 18: Exercise Therapy in Neuromuscular Disease

DOMS

• Z disk is the most vulnerable structure

• Type II fiber- biased damage (Lieber & FrideÂn 1988)

• Loss of desmin, inflammatory changes and necrosis in animals

• Older men are not as susceptible (Lavender and Nosaka; 2006)

Page 19: Exercise Therapy in Neuromuscular Disease

Physiologic Response to Exercise

• Neural adaptation: – Accounts for early strength gain with training

programs (2 weeks) – Increase in muscle strength without noticeable

hypertrophy• Muscular Adaptation:

– 6-8 weeks to develop – Increase in muscle cross-sectional area (muscle

hypertrophy) in response to resistive exercise – Fast twitch (type II) fibers more than type I

Page 20: Exercise Therapy in Neuromuscular Disease

Cross-transference

• Strength gain in the opposite, untrained limb following unilateral resistance training

• Due to neural adaptation• Improves the strength of a unmovable

injured limb or during post surgical period • Implication in research:

– Cannot use the opposite limb as control– 7.8-10% improvement in strength of the

untrained limb (Meta-analysis study)

Page 21: Exercise Therapy in Neuromuscular Disease

Neuromuscular Disease Spectrum

• Motor neuron disease (ALS, polio)

• Nerve roots or peripheral nerves

• Neuromuscular junction transmission (MG, LEMS)

• Myofiber – Acquired (IBM, DM, PM)– Congenital (MD,

BMD,DM, Mitochondrial)

Page 22: Exercise Therapy in Neuromuscular Disease

Questions to answer

Safe? Beneficial?

Page 23: Exercise Therapy in Neuromuscular Disease

Studies in NMDs • Limited number of studies• Methodological limitations

– Lack of good controlled studies due to the rarity of NMDs– Grouped subjects with different NMDs with different

disease type, severity, and rate of progression– Little uniformity regarding the type of exercise

interventions (aerobic, strengthening, or combinations of exercise regimens),duration of exercise, intensity of exercise therapy, and initial state of physical activity and fitness

– Lack of clearly identified primary and secondary outcome measures

• Strength, endurance, fatigue, cardiopulmonary function, functional ability, activities of daily living, anxiety, depression, wellbeing, and pain

Page 24: Exercise Therapy in Neuromuscular Disease

Muscular Dystrophies • Heterogeneous group of

hereditary muscle diseases

• Progressive muscle weakness

• Muscle fiber damage, inflammation, necrosis, and regeneration

• Defects in sarcolemmal and extracellular matrix proteins, essential in maintaining the cytoskeletal framework of the muscle fiber during muscle contraction

Page 25: Exercise Therapy in Neuromuscular Disease

DMD BMD Incidence 1 in 3,500 1 in 30,000

Age of Onset 3 to 5 yrs > 7 yrs

Dystrophin Mutation

Frameshift Mutation In-frame Mutation

CK Very high (5,000 to 20,000)

Presentation Proximal > Distal Symmetric Legs & Arms

Calf Hypertrophy

Failure to Walk 9 - 13 years 16-80 years

Cause of death Respiratory failure Cardiac

Page 26: Exercise Therapy in Neuromuscular Disease

Strengthening Exercise• Studies in dystrophin-deficient mdx mice

have shown that dystrophic muscle is more susceptible to contraction-induced muscle damage compared to healthy mice

• Available randomized control trials are small in size, with inconsistent methodologies and conflicting results

• General consensus is that high resistance strengthening exercises are contraindicated in patients with dystrophinopathy

Page 27: Exercise Therapy in Neuromuscular Disease

Unstable sarcolemma makes the muscle susceptible to mechanical stress , muscle fiber necrosis, fiber loss, and replacement with fibrotic tissue

Disruption of dystrophin down regulates nitric oxide synthase (nNOS), which leads to disregulation of blood flow to the muscle and functional muscle ischemia

Page 28: Exercise Therapy in Neuromuscular Disease

Tadalafil-Muscle Ischemia-BMD

“Tadalafil Alleviates Muscle Ischemia in Patients With Becker Muscular Dystrophy”•Randomized placebo-controlled crossover trial•Tadalafil (phosphodiesterase 5A inhibitor)•Functional muscle ischemia is alleviated and normal blood flow regulation is fully restored in the muscles of men with BMD•There were no adverse events or side effects

Martin et al 2012

Page 29: Exercise Therapy in Neuromuscular Disease

Endurance Training and BMD Method: •Eleven patients with BMD and seven healthy subjects•All patients were ambulant•Onset of symptoms at age 8 ± 2years•Asymptomatic cardiomyopathy (LVEF):35–45% in 3 patients •Forced vital capacity (FVC) was on average decreased by 14±2% (within normal limits)Primary Outcomes: VO2max, Plasma Ck, and self report questionnaire Intervention: Cycled 50, 30min sessions at 65% of their VO2max over 12 weeks, and six patients continued cycling for 1 year

Sveen et al 2008

Page 30: Exercise Therapy in Neuromuscular Disease

Endurance Training and BMDResults:

– Improved VO2max by 47± 11% in patients (P0.005)– Weekly CK levels did not increase with training– No change in the number of central nuclei, necrotic and

regenerating fibers– Strength in muscles involved in cycle exercise (knee

extension, and dorsi- and plantar-flexion) increased significantly by 13-40%.

– Cardiac pump function, measured by echocardiography, did not change with training

– All improvements and safety markers were maintained after 1 year of training

Conclusion: – Moderate endurance training is safe to increase exercise

performance and daily function in patients with BMD

Sveen et al 2008

Page 31: Exercise Therapy in Neuromuscular Disease

High Intensity Endurance Training“Creatine kinase response to high-intensity aerobic exercise in adult-onset muscular dystrophy”Method: •Fourteen patients with muscular dystrophy (BMD: 5, FSHD: 5 , LGMD2-I and LGMD2-A: 4 ) •Eight healthy subjects •5 cycling tests at 65, 75, 85 and 95 % of VO2 max•Heart rate and oxygen consumption were measured during tests•Plasma CK was measured before, immediately after, and 24 hours after exercise

Anderson et al 2013

Page 32: Exercise Therapy in Neuromuscular Disease

High Intensity Endurance Training

Results: •Plasma CK increased after all exercise tests in all patients •In persons affected by LGMD2A, LGMD2I, and FSHD, plasma CK declined to the pre-exercise level 24 hours after exercise•Plasma CK remained elevated 24 hours after exercise in persons with BMD (only after the 95% of VO2max test)•The subjects never scored higher than 3.5 on the leg pain VAS (immediately after exercise)

Anderson et al 2013

Page 33: Exercise Therapy in Neuromuscular Disease

High Intensity Endurance Training

Conclusion: •High-intensity aerobic exercise is generally well-tolerated in persons with LGMD2 and FSHD•Patients with BMD may be more prone to exercise induced damage•Closer supervision of training is warranted if high-intensity exercise is implemented

Anderson et al 2013

Page 34: Exercise Therapy in Neuromuscular Disease

Idiopathic Inflammatory Myopathies (IIM)

• Heterogeneous group of rare disorders that present with acute, subacute, or chronic muscle weakness

• Overlapping clinical manifestations• Divergent from the histopathological and

pathogenetic standpoints• Generally respond well to immunosuppressive

therapy• Inclusion body myositis (IBM), the most common

IIM in the elderly, is clinically, histopathologically and pathogenetically distinct

• IBM is refractory to all currently available therapies

Page 35: Exercise Therapy in Neuromuscular Disease

Exercise and IIM• Studies in active and chronic disease phase

have been reported• All demonstrated the safety and efficacy of

exercise• Neuromuscular specialists usually wait for the

first two to three months for strength and CK to start responding to pharmacotherapy before starting the strengthening exercise program

• Early mobilization is important to prevent flexion contractures

Dimachkie 2011

Page 36: Exercise Therapy in Neuromuscular Disease

Exercise and IBM (Arnardottir et al, 2003): •A home exercise program, five days a week for 12 weeks, was found to be safe in seven patients. There was no strength deterioration, no change in serum CK, and no increased in muscle inflammation on biopsy(Johnson et al., 2009): •Aerobic exercise program using a stationary cycle ergometer at 80% of the initial maximum heart rate (for two minutes less than the total time achieved during maximal aerobic test) combined with resistance isometric and isotonic exercises of the upper and lower limbs in a group of seven IBM cases. Besides demonstrating it to be safe, they found this exercise routine to improve aerobic capacity and muscle strength.

Dimachkie 2011

Page 37: Exercise Therapy in Neuromuscular Disease

Mitochondrial Myopathy • Heterogeneous group of metabolic muscle disorders• Mutation in either nuclear or mitochondrial DNA (mtDNA)• Brain and skeletal muscles are particularly susceptible • Single-organ to multisystem disorders (muscle weakness

or exercise intolerance, arrhythmia, dementia, movement disorders, stroke-like episodes, deafness, blindness, ophthalmoplegia, and seizures)

• Heteroplasty: mtDNA mutations coexist with wild-type mtDNA (Mild phenotypes have higher proportions of wild-type mtDNA)

• Mature muscle cells have a high degree of mtDNA mutations, whereas the level of mutations is low or undetectable in satellite cells

Page 38: Exercise Therapy in Neuromuscular Disease

Exercise in MT-Myopathy • Resistance exercise serves as stimulus for

satellite-cell induction within skeletal muscle, lowering the level of mutant mtDNA and improving oxidative capacity (Murphy et al 2008)

• The beneficial effects of endurance training have been reported in 8 published reports, with no adverse effects

• Hypothesized to induce mitochondrial biogenesis and capacity for oxidative phosphorylation improve function

Page 39: Exercise Therapy in Neuromuscular Disease

Amyotrophic Lateral Sclerosis (ALS)

• Progressive degenerative disease of the upper and lower motor neuron

• Majority of cases are sporadic (90%)• Hereditary defect in the superoxide dismutase

(SOD) gene (20%)• Studies of exercise on SOD deficient mice

suggest that endurance exercise training at moderate intensities slows disease progression, and increases lifespan

• High-intensity exercise showed no improvement or hastened symptoms and death

Page 40: Exercise Therapy in Neuromuscular Disease

Exercise and ALS

• Twenty-five patients were randomized to receive a moderate daily exercise program (n=14) or control (n=11)

• Outcome measures at baseline and after 3, 6, 9 and 12 months– Manual muscle strength testing– Ashworth spasticity scale– ALS functional rating scale (ALSFRS)– Visual analog scale for pain – Quality-of-life scale (SF-36)

Drory et al 2001

Page 41: Exercise Therapy in Neuromuscular Disease

Exercise and ALS • At 3 months, patients who performed regular

exercise showed less deterioration on FRS and Ashworth scales, but not on other parameters

• At 6 months, there was no significant difference between groups, although a trend towards less deterioration in the treated group on most scales was observed

• At 9 and 12 months, there were too few patients in each group for statistical evaluation

Page 42: Exercise Therapy in Neuromuscular Disease

Exercise and ALS Method:27 patients with a diagnosis of ALS, FVCof ≥90% predicted, and ALS Functional Rating Scale (ALSFRS) score of 30 or greater were randomly assigned to a resistance exercise group (n=13) or to a usual care group (n=14)

Results: - Eight resistance exercise subjects and 10 usual care subjects completed the trial- At 6 months, the resistance exercise group had significantly higher ALSFRS and SF-36 scores -No adverse events -Less decline in leg strength measured by MVIC

Bello- Haas et al 2007

Page 43: Exercise Therapy in Neuromuscular Disease

Post Polio Syndrome • Affects individuals who had a confirmed case

of polio with a partial or fairly complete neurological and functional recovery after the acute episode

• At least 15 years of neurological and functional stability

• Presenting with gradual or abrupt onset of new muscle weakness, muscle atrophy, muscle pain, and fatigue

• Persists for more than 1 year

Page 44: Exercise Therapy in Neuromuscular Disease

Exercise in PPS • European Federation of Neurological Society

(ENFS) task force determined that both aerobic training and progressive resistance exercise training can benefit individuals with PPS (2006)

• Systematic analysis by Cup et al in 2008 determined that there is insufficient evidence to assess the effectiveness of muscle strengthening exercises, aerobic exercises, or a combination of these exercises in individuals with PPS

Abresch et al 2009

Page 45: Exercise Therapy in Neuromuscular Disease

Class Remote Weakness

Recent Weakness

Exam * EMG/NCS**

I No No Normal Normal

II No No Normal Chronic denervation

III Residual No Abnormal Chronic ± Active denervation

IV Residual Yes Abnormal Chronic ± Active denervation

V Residual yes Abnormal ↓insertional activity Chronic ± Active denervation

*: Visible atrophy, Manual muscle testing, DTRs, sensation **: biceps, triceps, and FDI in UE and Med gastroc, TA, and Quad in LE

Halstead et al 2010

Page 46: Exercise Therapy in Neuromuscular Disease

Class Remote Weakness

Recent Weakness

Exam * EMG/NCS**

I No No Normal Normal

II No No Normal Chronic denervation

III Residual No Abnormal Chronic ± Active denervation

IV Residual Yes Abnormal Chronic ± Active denervation

V Residual yes Abnormal ↓insertional activity Chronic ± Active denervation

*: Visible atrophy, Manual muscle testing, DTRs, sensation **: biceps, triceps, and FDI in UE and Med gastroc, TA, and Quad in LE

Page 47: Exercise Therapy in Neuromuscular Disease

Proposed Exercise in PPS

• Class 1: – Moderate intensity: 60-80% maximal HR – Duration: 15-30 min– Frequency: 3-5/week Examples:

• Swimming 25-35 yards/min • Walking 5-6 mph • Bicycle riding 12-14 mph

Halstead et al 2010

Page 48: Exercise Therapy in Neuromuscular Disease

Class Remote Weakness

Recent Weakness

Exam * EMG/NCS**

I No No Normal Normal

II No No Normal Chronic denervation

III Residual No Abnormal Chronic ± Active denervation

IV Residual Yes Abnormal Chronic ± Active denervation

V Residual yes Abnormal ↓insertional activity Chronic ± Active denervation

*: Visible atrophy, Manual muscle testing, DTRs, sensation **: biceps, triceps, and FDI in UE and Med gastroc, TA, and Quad in LE

Page 49: Exercise Therapy in Neuromuscular Disease

Proposed Exercise in PPS

• Class II:– Moderate intensity: 60-80% maximal HR – Duration: 15-30 min– Frequency: 3-4/week on alternate days – Pacing: perform 4-5 min, rest 1 min *Decrease if pain, fatigue or new weakness

Halstead et al 2010

Page 50: Exercise Therapy in Neuromuscular Disease

Class Remote Weakness

Recent Weakness

Exam * EMG/NCS**

I No No Normal Normal

II No No Normal Chronic denervation

III Residual No Abnormal Chronic ± Active denervation

IV Residual Yes Abnormal Chronic ± Active denervation

V Residual yes Abnormal ↓insertional activity Chronic ± Active denervation

*: Visible atrophy, Manual muscle testing, DTRs, sensation **: biceps, triceps, and FDI in UE and Med gastroc, TA, and Quad in LE

Page 51: Exercise Therapy in Neuromuscular Disease

Proposed Exercise in PPS

• Class III: – Low intensity: 40-60% of max HR – Duration: 15-20 min– Frequency: 3-4/week – Pacing: Resting 1 min/2-3 min of activity *modify if new weakness, pain or fatigue

Halstead et al 2010

Page 52: Exercise Therapy in Neuromuscular Disease

Class Remote Weakness

Recent Weakness

Exam * EMG/NCS**

I No No Normal Normal

II No No Normal Chronic denervation

III Residual No Abnormal Chronic ± Active denervation

IV Residual Yes Abnormal Chronic ± Active denervation

V Residual yes Abnormal ↓insertional activity Chronic ± Active denervation

*: Visible atrophy, Manual muscle testing, DTRs, sensation **: biceps, triceps, and FDI in UE and Med gastroc, TA, and Quad in LE

Page 53: Exercise Therapy in Neuromuscular Disease

Proposed Exercise in PPS

• Class IV: – Trial of rest to exclude overuse weakness – Daily active/passive stretching program – No cardiopulmonary aerobic exercise – If overuse is excluded, trial of monitored, non-

fatiguing, progressive resistive exercise program

– If overuse weakness, modify activity, use bracing, scooter, etc.

Halstead et al 2010

Page 54: Exercise Therapy in Neuromuscular Disease

Class Remote Weakness

Recent Weakness

Exam * EMG/NCS**

I No No Normal Normal

II No No Normal Chronic denervation

III Residual No Abnormal Chronic ± Active denervation

IV Residual Yes Abnormal Chronic ± Active denervation

V Residual yes Abnormal ↓insertional activity Chronic ± Active denervation

*: Visible atrophy, Manual muscle testing, DTRs, sensation **: biceps, triceps, and FDI in UE and Med gastroc, TA, and Quad in LE

Page 55: Exercise Therapy in Neuromuscular Disease

Proposed Exercise in PPS

• Class V: – Performing activities of daily living – Bracing and/or wheelchair usually needed

Halstead et al 2010

Page 56: Exercise Therapy in Neuromuscular Disease

Diabetic Neuropathy • Pilot study • Seventeen subjects (8 males/9 females; age 58.4±5.98; duration of

diabetes 12.4±12.2 years) • 10- week supervised, moderately intense aerobic and resistance

exercise program• Outcome measures:

– Pain (visual analog scale)– Michigan Neuropathy Screening Instrument (MNSI)– Intraepidermal nerve fiber (IENF) density and branching

RESULTS: • Significant reductions in pain, neuropathic symptoms, and increased

intraepidermal nerve fiber branching from a proximal skin biopsy

Pasnoor et al 2012

Page 57: Exercise Therapy in Neuromuscular Disease

Conclusion

1. Individuals with NMDs should adopt an active lifestyle for its physical and psychological benefits2. Stretching and range-of-motion exercises may be helpful in decreasing the discomfort due to the limited joint mobility 3. Moderate resistance exercise should be given to patients with antigravity strength or better to maintain strength

Abresch et al 2012

Page 58: Exercise Therapy in Neuromuscular Disease

Conclusion 4. Moderate aerobic exercise should be given to prevent deconditioning and loss of cardiopulmonary fitness5. High-intensity exercises relative to an individual’s strength should be avoided6. The intensity and frequency of exercise should be tailored to individual's level of physical fitness and need7. The effects of exercise should be closely monitored 

Abresch et al 2012

Page 59: Exercise Therapy in Neuromuscular Disease

What to Tell Patients?

• Moderate: • 40-60% VO2 Max or 60%of maximum HR • Walking as fast as 100 steps per minute • Breathing quickens, but not out of breath• Develop a light sweat after about 10

minutes of activity• Can carry on a conversation, but you can't

sing

Page 60: Exercise Therapy in Neuromuscular Disease

What to Tell Patients?

Vigorous exercise intensity •Breathing is deep and rapid•Develop a sweat after a few minutes of activity•Cannot say more than a few words without pausing for breath

Page 61: Exercise Therapy in Neuromuscular Disease

References • Alexanderson H, Lundberg IE. The role of exercise in the

rehabilitation of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2005;17:164-71.

• Arnardottir, S., Alexanderson, H., Lundberg, I.E., Borg, K., 2003. Sporadic inclusion bodymyositis: pilot study on the effects of a home exercise program on muscle function,histopathology and inflammatory reaction. J. Rehabil. Med. 35 (1), 31–35.

• Cup EH, Pieterse AJ, Knuijt S, et al. Referral of patients with neuromuscular disease to occupational therapy, physical therapy and speech therapy: usual practice versus multidisciplinary advice. Disabil Rehabil 2007;29:717-26.

• Dimachkie MM.J Neuroimmunol. 2011 Feb;231(1-2):32-42. doi: 10.1016/j.jneuroim.2010.10.013. Epub 2010 Nov 18. Review.

• Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001;191:133-7.

• FrideÂn, J. & Lieber, R.L. 1998. Segmental muscle ®ber lesionsafter repetitive eccentric contractions. Cell Tissue Res 293, 165±171

Page 62: Exercise Therapy in Neuromuscular Disease

References • Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: an

effective therapy in McArdle’s disease. Ann Neurol 2006;59:922-8.• HALSTEADL,. S . 1991. Assessment and differential diagnosis for

post-polio syndrome.Orthopedics 14(11): 1209-12 17.• Hartling L, McAlister FA, Rowe BH, Ezekowitz J, Friesen C, Klassen

TP. Challenges in systematic reviews of therapeutic devices and procedures. Ann Intern Med 2005;142:1100-11.

• Johnson, L.G., Collier, K.E., Edwards, D.J., Philippe, D.L., Eastwood, P.R., Walters, S.E.,Thickbroom, G.W., Mastaglia, F.L., 2009. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J. Clin. Neuromuscul. Dis. 10 (4), 178–184.

• Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE, Gurudevan SV, Anene F, Elashoff RM, Thomas GD, Victor RG. Sci Transl Med. 2012 Nov 28;4(162):162ra155.

Page 63: Exercise Therapy in Neuromuscular Disease

References • Neuromuscular Disorders, treatment and management, Tulio E. Bertonrini,

115-136. • Olsen DB, Orngreen MC, Vissing J. Aerobic training improves exercise

performance in facioscapulohumeral muscular dystrophy.Neurology 2005;64:1064-6.

• Taivassalo T, Haller RG. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 2005;37:2094-101.

• Van der Kooi EL, Lindeman E, Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Re 2005;(1):CD003907

• Van Tulder MW, Assendelft WJ, Koes BW, Bouter LM. Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine 1997;22:2323- 30.

• Taivassalo T, De Stefano N, Argov Z, et al. Effects of aerobic training in patients with mitochondrial myopathies. Neurology 1998;50:1055-60.

• Taivassalo T, De Stefano N, Chen J, Karpati G, Arnold DL, Argov Z. Short-term aerobic training response in chronic myopathies. Muscle Nerve 1999;22:1239-43.

• McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995;74: S70–S92.

Page 64: Exercise Therapy in Neuromuscular Disease

Thank You